Drug intelligence / Profile preview

AB19

Development stage: Unknown
Lead developer: McGill University Health Centre

Overview

AB19: sourced facts only. name: "The results showed that AB19 pulled down MET (its primary target) and many other kinases, including LCK, Src, EPHA2, and FAK1 that play an important role in cancer progression." [DOI:10.1158/1538-7445.am2024-lb054]; target: "The results showed that AB19 pulled down MET (its primary target) and many other kinases, including LCK, Src, EPHA2, and FAK1 that play an important role in cancer progression." [DOI:10.1158/1538-7445.am2024-lb054]; developer: "1McGill University Health Center, Montréal, Quebec, Canada." [DOI:10.1158/1538-7445.am2024-lb054]

Targets

MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on AB19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB19.